The mudslinging between Allergan and Valeant got more intense on Monday. But it was Morgan Stanley bankers who found themselves caught in the crossfire.
Allergan, which is fending off a $53 billion takeover bid by Valeant, released emails sent by senior Morgan Stanley bankers appearing to denigrate Valeant and its business strategy.